Lauren Appell Institution-verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Physician
faculty
Research Areas
Biography and Research Information
OverviewAI-generated summary
Lauren Appell's research focuses on pediatric hematology and oncology, with a particular interest in complex cases and treatment outcomes. Her work has explored the use of granulocyte infusions for children with severe neutropenia and fungal infections, and she has investigated the efficacy of CAR-T cell therapy for post-transplant lymphoproliferative disorders in pediatric heart transplant recipients. Appell has also studied inflammatory myositis as a late complication of hematopoietic stem cell transplantation (HSCT) in patients with primary immune deficiency disease. Additional research interests include central nervous system-symptomatic hyperammonemia following enzyme replacement therapy and the diagnosis of HHV-6 encephalitis after bone marrow transplantation. She has also been involved in studies evaluating exercise regimens for pediatric patients with acute lymphoblastic leukemia.
Metrics
- h-index: 2
- Publications: 15
- Citations: 15
Selected Publications
-
Central nervous system-symptomatic hyperammonemia following recombinant crisantaspase Pseudomonas fluorescens (2026)
-
A supervised STreNgth & Outpatient Exercise Regimen in pediatric patients with Acute Lymphoblastic Leukemia (STRONGER ALL) (2026)
-
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel (2025)
-
130 A supervised strength and outpatient exercise regimen in pediatric patients with acute lymphoblastic leukemia (STRONGER ALL) (2025)
-
Evaluation of recurrent and recalcitrant warts in a deaf adolescent male reveals GATA2 deficiency (2024)
-
Inhibition of DNA-Pkcs As Novel Therapy for the Prevention of Acute Gvhd Following Hematopoietic Stem Cell Transplantation (2021)
Grants & Funding
Collaboration Network
Top Collaborators
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-Pkcs As Novel Therapy for the Prevention of Acute Gvhd Following Hematopoietic Stem Cell Transplantation
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells
- Inflammatory Myositis As Late Complication of HSCT in Primary Immune Deficiency Disease
- CAR-T for Pediatric Diffuse Large B-Cell Lymphoma Type Post-Transplant Lymphoproliferative Disorder in a Post Heart Transplant Patient
- Evaluation of recurrent and recalcitrant warts in a deaf adolescent male reveals GATA2 deficiency
- Improving Time to Antibiotic Administration with Initial Fever in HCT Recipients
- CAR-T for Pediatric Diffuse Large B-Cell Lymphoma Type Post-Transplant Lymphoproliferative Disorder in a Post Heart Transplant Patient
- Evaluation of recurrent and recalcitrant warts in a deaf adolescent male reveals GATA2 deficiency
- Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease
- 130 A supervised strength and outpatient exercise regimen in pediatric patients with acute lymphoblastic leukemia (STRONGER ALL)
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- DNA-PKcs is required for the activation and cytotoxicity of CD8+ effector T cells
- Inflammatory Myositis As Late Complication of HSCT in Primary Immune Deficiency Disease
- CAR-T for Pediatric Diffuse Large B-Cell Lymphoma Type Post-Transplant Lymphoproliferative Disorder in a Post Heart Transplant Patient
- Improving Time to Antibiotic Administration with Initial Fever in HCT Recipients
- Inflammatory Myositis As Late Complication of HSCT in Primary Immune Deficiency Disease
- CAR-T for Pediatric Diffuse Large B-Cell Lymphoma Type Post-Transplant Lymphoproliferative Disorder in a Post Heart Transplant Patient
- Improving Time to Antibiotic Administration with Initial Fever in HCT Recipients
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4 <sup>+</sup> helper and CD8 <sup>+</sup> effector T cells
- Inflammatory Myositis As Late Complication of HSCT in Primary Immune Deficiency Disease
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
- Chemical inhibition of <scp>DNA‐PKcs</scp> impairs the activation and cytotoxicity of <scp>CD4</scp><sup>+</sup> helper and <scp>CD8</scp><sup>+</sup> effector T cells
Similar Researchers
Based on overlapping research topics